Abstract
Inflammatory bowel diseases are most likely caused by an excessive immune reaction to the gut flora in genetically predisposed individuals. This excessive reaction depends on an imbalance of pro- and anti-inflammatory processes. T cells are central effector cells of the immune reaction in inflammatory bowel diseases. Most new substances that will be available for treating Crohn's disease and ulcerative colitis in the near future target the activation, migration, and effector functions of T helper cells. Other substances currently being evaluated attempt to bolster epithelial defence mechanisms. Clinical remission is still the therapeutic goal in inflammatory bowel diseases. Whether "mucosal healing" can lead to a better prognosis remains a matter of debate.
| Translated title of the contribution | New treatments for chronic inflammatory intestinal diseases: fffrom bench to bedside |
|---|---|
| Original language | German |
| Pages (from-to) | 423-429 |
| Number of pages | 7 |
| Journal | Gastroenterologe |
| Volume | 2 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 2007 |
ASJC Scopus subject areas
- Gastroenterology